Cytovale vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytovale is developing a rapid point-of-care sepsis diagnostic — IntelliSep — that measures immune cell deformability via microfluidics to detect sepsis in ~8 minutes; received FDA Breakthrough Device Designation; raised $88M total;
About
Cytovale is a medical technology company headquartered in San Francisco, California, founded in 2014 by Lydia Sohn and others, with roots in biophysics research at the University of California, Berkeley. The company is developing the IntelliSep test — a rapid, near-patient diagnostic for sepsis that uses a proprietary microfluidic technology to measure the mechanical properties (deformability) of immune cells in whole blood. Sepsis — a life-threatening systemic immune response to infection — kills approximately 270,000 Americans annually and is the leading cause of hospital mortality, yet current diagnostic approaches (blood cultures, lactate, clinical scoring systems) are slow, non-specific, and frequently fail to identify sepsis before it progresses to organ failure and septic shock.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.